Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
Phase 2/3, Not yet recruiting, 920 people, Oct 22, 2026
NCT07605364
Phase 2/3, Not yet recruiting, 422 people, May 26, 2026
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Phase 3, Recruiting, 466 people, Jan 7, 2026
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Phase 2, Recruiting, 164 people, Dec 19, 2025
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Recruiting, 420 people, Dec 16, 2025
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Phase 3, Recruiting, 408 people, Oct 14, 2025
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Phase 3, Recruiting, 1,524 people, Oct 1, 2025
Family Communications After Genetic Testing
Recruiting, 4,186 people, Aug 27, 2025
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Recruiting, 535 people, Jul 29, 2025
Distance-Based Exercise to Preserve Function and Prevent Disability
Recruiting, 104 people, Jul 11, 2025
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Phase 3, Recruiting, 330 people, May 31, 2025
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Phase 3, Recruiting, 228 people, May 28, 2025
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Phase 3, Recruiting, 1,260 people, Apr 17, 2025
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Phase 3, Recruiting, 1,524 people, Mar 14, 2025
NCT06671912
Phase 3, Suspended, 1,556 people, Nov 4, 2024
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Phase 3, Recruiting, 1,040 people, Oct 28, 2024
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Phase 2, Recruiting, 474 people, Oct 9, 2024
NCT06632327
Phase 3, Active, not recruiting, 37 people, Oct 9, 2024
NCT06592924
Collaborator, Phase 3, Recruiting, 830 people, Sep 19, 2024
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1/2, Suspended, 88 people, Jan 30, 2024